Valiant Laboratories Ltd
NSE: VALIANTLAB · Pharmaceuticals · sector
₹125.87NSE close 2026-10-26
Key numbers
Market cap₹684 cr
Price₹125.87
52w high / low₹141 / ₹50
P/E42.7xSector median 27.9x
P/B2.2xSector median 2.9x
Book value₹57.2
Dividend yield–Sector median 0.48%
ROE5.9%Sector median 11.7%
ROCE7.7%Sector median 12.3%
OPM10.9%Sector median 14.0%
Debt / equity0.14xSector median 0.16x
EV/EBITDA20.9xSector median 18.6x
Interest cover9.5x
Current ratio1.91x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG0.00x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹33 cr vs borrowings ₹45 cr (FY26): borrowings are higher by ₹12 cr.
- Operating profit covered interest 9.5x in the last 12 months.
- Operating cash flow was below net profit in 1 of the last 3 years (FY26).
- Net loss in 2 of the last 8 quarters.
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 16% of net profit in the last 12 months.
- Debtor days went from 92 (FY24) to 144 (FY26).
- No dividend in the last 3 financial years.
- Price ₹125.87 on 2026-10-26: -11.0% from the 52-week high, +154.2% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹134.65 · low ₹51.49
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21 | 35 | 58 | 47 | 46 | 52 | 92 | 115 |
| EBITDA | -7 | 1 | 4 | 2 | 0 | -1 | 5 | 29 |
| OPM % | -31.4% | 1.8% | 6.6% | 5.1% | 0.2% | -1.7% | 5.2% | 25.4% |
| Other income | 3 | 2 | -2 | 1 | 1 | 1 | 0 | 1 |
| Net profit | -5 | 2 | 1 | 2 | 0 | -7 | 2 | 21 |
| EPS (₹) | -1.09 | 0.54 | 0.16 | 0.42 | 0.04 | -1.30 | 0.32 | 3.89 |
| Revenue YoY | +115.1% | +48.9% | +59.2% | +146.2% | ||||
| Profit YoY | – | -400.4% | +151.4% | +1,059.3% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|
| Revenue | 182 | 133 | 237 | 306 |
| EBITDA | -8 | -5 | 6 | 33 |
| Net profit | 0 | -2 | -3 | 16 |
| EPS (₹) | 0.13 | -0.51 | -0.51 | 2.95 |
| Revenue growth | -26.7% | +78.0% | +89.6% | |
| Profit growth | -787.5% | – | +12,326.7% | |
| Dividend / share (₹) | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | +89.6% |
| Net profit | – | – | +12,326.7% |
| EPS | – | – | – |
| Share price | – | +9.6% (2y) | +58.1% |
Balance sheet
| ₹ cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Shareholders' equity | 237 | 234 | 311 |
| Borrowings | 76 | 121 | 45 |
| Cash & equivalents | 144 | 76 | 33 |
| Total assets | 343 | 401 | 464 |
| Fixed assets | 50 | 48 | 227 |
| Capital work in progress | 43 | 156 | 6 |
| Investments | 0 | 0 | 0 |
| Receivables | 46 | 72 | 94 |
| Inventory | 10 | 4 | 45 |
| Payables | 26 | 41 | 94 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Cash from operations | 2 | 1 | -10 |
| Cash from investing | -144 | -53 | 7 |
| Cash from financing | 152 | 45 | 2 |
| Capex | 46 | 114 | 34 |
| Free cash flow | -44 | -113 | -45 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| ROE % | 0.1% | -0.9% | -1.1% |
| ROCE % | -0.2% | -0.4% | 0.8% |
| Debtor days | 92 | 197 | 144 |
| Inventory days | 22 | 12 | 84 |
| Payable days | 56 | 127 | 174 |
| Cash conversion cycle (days) | 58 | 82 | 54 |
| Working capital days | 394 | 364 | 167 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 74.94% |
| FIIs | 0.07% |
| DIIs | 0.08% |
| of which Mutual funds | 0.00% |
| of which Insurance | 0.00% |
| Government | 0.00% |
| Public (non-institutions) | 24.91% |
| Quarter | Mar 2025 | Jun 2025 | Aug 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% |
| Promoter group | % |
|---|---|
| Dhanvallabh Ventures LLP | 46.84% |
| Santosh Shantilal Vora | 7.50% |
| Shantilal Shivji Vora | 7.50% |
| Paresh Shashikant Shah | 7.49% |
| Kanchan Shantilal Vora | 3.72% |
| Chandrakant Vallabhaji Gogri | 1.87% |
| Rachi Santosh Vora | 0.02% |
| Varsha Paresh Shah | 0.01% |
| Sangita Manoj Jain | 0.00% |
| Sona Enterprises | 0.00% |
| Chetan Dresses | 0.00% |
| Sagar Chemicals | 0.00% |
| Shantilal Vora and Sons LLP | 0.00% |
| Valiant Organics Limited | 0.00% |
| Valiant Laboratories Limited Employees Group Gratuity Fund | 0.00% |
| Public holders above 1% | % |
|---|---|
| Anil Vishanji Dedhia | 1.84% |
14,618 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| VALIANTLAB | ₹684 cr | 42.7x | 2.2x | 5.9% | 7.7% | 10.9% | – | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2025-07-18 | Rights | Rights 1:4 @ Premium Rs 65/- |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | VALIANTLAB |
| BSE code | 543998 |
| ISIN | INE0JWS01017 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.